BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $90.32, for a total value of $903,200.00. Following the completion of the transaction, the chief executive officer now directly owns 235,894 shares in the company, valued at $21,305,946.08. The transaction was disclosed in a filing with the SEC, which is available at this link.
Jean Jacques Bienaime also recently made the following trade(s):
- On Saturday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $89.61, for a total value of $896,100.00.
- On Friday, December 29th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $89.75, for a total value of $1,795,000.00.
BioMarin Pharmaceutical Inc. (BMRN) opened at $89.90 on Thursday. The company has a market capitalization of $15,850.00, a PE ratio of -108.71 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 12-month low of $80.10 and a 12-month high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.
Several equities analysts have recently weighed in on the company. Leerink Swann reissued an “outperform” rating and set a $142.00 price target (up from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. SunTrust Banks set a $115.00 target price on BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, October 19th. Wedbush raised BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a report on Thursday, December 14th. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Finally, BidaskClub raised BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, December 16th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $111.60.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Manhattan Co. grew its position in BioMarin Pharmaceutical by 104.2% in the fourth quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 625 shares in the last quarter. Toronto Dominion Bank lifted its stake in BioMarin Pharmaceutical by 12.9% in the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 243 shares during the last quarter. Commerce Bank bought a new stake in BioMarin Pharmaceutical in the third quarter worth about $209,000. IFG Advisory LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter worth about $212,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in BioMarin Pharmaceutical in the second quarter worth about $213,000. Institutional investors own 99.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/01/insider-selling-biomarin-pharmaceutical-inc-bmrn-ceo-sells-10000-shares-of-stock.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.